Skip to content

Injection Options and Further Insights for Spinal Muscular Atrophy

Injections for Spinal Muscular Atrophy: Varieties Explored

Injections for Spinal Muscular Atrophy: Varieties and Further Information
Injections for Spinal Muscular Atrophy: Varieties and Further Information

Injection Options and Further Insights for Spinal Muscular Atrophy

In a significant development for those affected by Spinal Muscular Atrophy (SMA), the Food and Drug Administration (FDA) has approved two treatments for the condition: Nusinersen (Spinraza) and Onasemnene abeparovec-xioi (Zolgensma).

Nusinersen, the first FDA-approved treatment for SMA, was introduced in 2016. It works by increasing the production of the SMN protein, a vital protein that is lacking in individuals with SMA. This increase helps to reduce the symptoms of the disease.

Onasemnene abeparovec-xioi, approved by the FDA in 2019, takes a different approach. It works by replacing the function of the SMN1 gene, delivering a new working version of the gene to the motor neurons. This novel method has shown promise in improving muscle function, movement, and survival in patients.

Both treatments require a medical professional's administration. For Nusinersen, doctors inject the drug into the spinal canal after administering a local anesthetic. Onasemnene abeparovec-xioi, on the other hand, is administered through intravenous infusion.

While these treatments offer a significant step forward, it's important to note that each case of SMA is unique. A healthcare professional can advise on the suitability of treatments on an individual basis.

In addition to these treatments, there are various other management strategies for SMA. Rehabilitation, physical therapy, occupational therapy, and the use of assistive devices like mobility aids are all options that can help manage the condition.

SMA affects individuals in different ways, with different types and severities. For instance, people with SMA type 1 have changes in a gene called the survival motor neuron gene 1 (SMN1), which means their bodies do not produce enough survival motor neuron (SMN) protein. More information about infantile SMA, distal SMA, adult-onset SMA, and other types can be found online.

Remember, it's crucial to consult your doctor for accurate and personalised information about SMA injections and other aspects of managing the condition. With these new treatments and a better understanding of the disease, there is hope for a brighter future for those affected by SMA.

Read also:

Latest